Quoin Pharmaceuticals Ltd ADR(QNRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:10 PM ET (Korea 10/1 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -14.93 | Insider Own | - | Shs Outstand | 2.0M | Perf Week | -32.44% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 56.67% | Insider Trans | - | Shs Float | - | Perf Month | -26.69% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -1.53 | Inst Own | 70.34% | Short Float | - | Perf Quarter | -3.18% |
| Income | -0.02B | P/S | - | EPS this Y | 58.72% | Inst Trans | 6.95% | Short Ratio | 0.23 | Perf Half Y | -30.91% |
| Sales | 0.00B | P/B | 2.33 | EPS next 5Y | 59% | ROA | -179.96% | Short Interest | 0.13M | Perf YTD | -68.4% |
| Book/sh | 1.96 | P/C | 0.85 | EPS past 3/5Y | 2.37% 61.71% | ROE | -579.57% | 52W High | -89.09% ($41.80) | Perf Year | -36.58% |
| Cash/sh | 5.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -477.79% | 52W Low | 40.31% ($3.25) | Perf 3Y | -96.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.98% | Gross Margin | - | Volatility(W/M) | 13.96% 10.36% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.64 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.76 | EPS Q/Q | 98.79% | Profit Margin | - | RSI (14) | 29.74 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.76 | Sales Q/Q | - | SMA20 | -31.17% ($6.63) | Beta | 1.55 | Target Price | $23.8 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | -19.3% ($5.65) | Rel Volume | 0.26 | Prev Close | $4.88 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -18.01% - | SMA200 | -35.05% ($7.02) | Avg Volume(3M) | 0.54M | Price | $4.56 |
| IPO | 2016/7/29 | Option/Short | No/Yes | Trades | 528 | Volume | 139,180 | Change | -6.56% |
Crown Pharmaceuticals () is a late-stage clinical specialty pharmaceutical company focused on rare and underserved skin diseases. Its lead candidate, QRX003, is a topical lotion developed to treat Netherton Syndrome, a condition caused by a deficiency of the LEKTI protein. QRX003 has secured designations from both the U.S. FDA and the European EMA as an orphan drug, as well as an FDA Rare Pediatric Disease designation, and two pivotal trials for systemic application are currently underway, making it a small-cap dermatology biotech.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual That is 26% of its average volume.
QNRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +58.7% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 70.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SURI Simplify Propel Opportunities ETF <0.01% It ranks #515 of 592 in the industry
Based on market cap of $9M.
APRE#513 Aprea Therapeutics Inc $9M PER - 
IMRN#514 Immuron Limited ADR $9M PER - QNRX#515 Quoin Pharmaceuticals Ltd ADR $9M PER - 
TRAW#516 Traws Pharma Inc $9M PER - 
ENLV#517 Enlivex Ltd $9M PER - 
FAQ
What kind of company is QNRX?
QNRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of QNRX?
The market cap of QNRX is approximately $9M, ranking 5,517 within its sector.
What is the 52-week high and low for QNRX?
QNRX has recorded a 52-week high of $41.80 and a low of $3.25.
